Author

Masashi Shimura

Observed name: M. Shimura

Observed institutions: University of Tsukuba, MSD K.K. (Japan), Taiho Pharmaceutical (Japan), Taiho Oncology (United States)

ORCID: 0000-0003-1233-4588

Observed ORCID: 0000-0003-1233-4588

OpenAlex ID: A5029250198

Peritoneal metastasis as a predictive factor for nab-paclitaxel in patients with pretreated advanced gastric cancer: an exploratory analysis of the phase III ABSOLUTE trial

2018 · Atsuo Takashima, Kohei Shitara, et al. · Gastric Cancer · 45

PDF

Practical characteristics of adaptive design in phase 2 and 3 clinical trials

2017 · A. Sato, M. Shimura, et al. · Journal of Clinical Pharmacy and Therapeutics · 33

PDF

Efficacy of Trabectedin in Patients with Advanced Translocation-Related Sarcomas: Pooled Analysis of Two Phase II Studies

2017 · Mitsuru Takahashi, Shunji Takahashi, et al. · The Oncologist · 31

PDF

Genomic correlates of response and resistance to the irreversible FGFR1-4 inhibitor futibatinib based on biopsy and circulating tumor DNA profiling

2024 · L. Goyal, D. DiToro, et al. · Annals of Oncology · 26

PDF

Safety Profile and Adverse Event Management for Futibatinib, An Irreversible FGFR1–4 Inhibitor: Pooled Safety Analysis of 469 Patients

2024 · Funda Meric-Bernstam, Antoine Hollebecque, et al. · Clinical Cancer Research · 20

PDF

Futibatinib plus pembrolizumab in patients (pts) with advanced or metastatic urothelial carcinoma (mUC): Preliminary safety results from a phase 2 study.

2022 · Vadim S Koshkin, Guru P. Sonpavde, et al. · Journal of Clinical Oncology · 19

Comparison of conditional bias-adjusted estimators for interim analysis in clinical trials with survival data

2017 · Masashi Shimura, Masahiko Gosho, et al. · Statistics in Medicine · 13

Effect of early tumor response on the health-related quality of life among patients on second-line chemotherapy for advanced gastric cancer in the ABSOLUTE trial

2020 · Kazumasa Fujitani, Kohei Shitara, et al. · Gastric Cancer · 12

PDF

Conditional estimation using prior information in 2‐stage group sequential designs assuming asymptotic normality when the trial terminated early

2018 · Masashi Shimura, Kazushi Maruo, et al. · Pharmaceutical Statistics · 7

Assessment of Hazard Ratios in Oncology Clinical Trials Terminated Early for Superiority

2020 · Masashi Shimura, Shogo Nomura, et al. · JAMA Network Open · 6

PDF

Abstract RF01-04: Final results from the phase 2, open-label FOENIX-MBC2 study: efficacy and safety of futibatinib in adult patients with locally advanced/metastatic HR+/HER2− breast cancer harboring high-level FGFR1 gene amplification

2024 · Senthil Damodaran, Fabrice André, et al. · Cancer Research · 5

Reducing overestimation of the treatment effect by interim analysis when designing clinical trials

2018 · Masashi Shimura · Journal of Clinical Pharmacy and Therapeutics · 5

PDF

Abstract P1-18-35: Futibatinib in combination with fulvestrant in patients with metastatic breast cancer (MBC) harboring high-level FGFR1 amplification: Preliminary data from a phase 2 study

2022 · Senthil Damodaran, Nisha Unni, et al. · Cancer Research · 3

Management (mgmt) of futibatinib-associated adverse events (AEs) in patients (pts) with advanced cancers: Results of a pooled analysis.

2023 · Funda Meric-Bernstam, Antoine Hollebecque, et al. · Journal of Clinical Oncology · 2

PDF

Pembrolizumab for Early‐Stage Triple‐Negative Breast Cancer: KEYNOTE ‐522 Japan Subgroup Analysis

2026 · Masato Takahashi, Hirofumi Mukai, et al. · Cancer Science · 1

PDF

Abstract PO4-06-07: Efficacy and safety of futibatinib in patients with locally advanced/metastatic triple-negative breast cancer harboring FGFR2 gene amplification: final results from the phase 2, open-label FOENIX-MBC2 study

2024 · Antonio Giordano, Nisha Unni, et al. · Cancer Research · 1

Supplementary Table S9 from Safety Profile and Adverse Event Management for Futibatinib, An Irreversible FGFR1–4 Inhibitor: Pooled Safety Analysis of 469 Patients